TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Abbreviated Quality of Life Scale (A-QLS) Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recovery Assessment Scale (RAS) Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With SLE Responder Index (SRI)-4 Response Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of IgG and IgM anti-SARS CoV2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the effect curve for CD34+ (AUECCD34+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed value for CD34+ (CD34+max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum filgrastim concentration versus time curve from time zero to 24 hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum filgrastim concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of ABT-199
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak concentration (Cmax), trough concentration (Ctrough), and area under the concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Completing Treatment Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant Satisfaction With Study Procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Reported Function and Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CD62L levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Hospital Onset C. difficile Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Failure of second-line drug treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of Covid positive patients presenting for surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long term satisfaction of patients post INTRACOR treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electrocardiograms (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Loss in fractional flow reserve (FFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exacerbation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events attributed to Tcm adoptive transfer
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in dose of inhaled corticosteroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in particle concentration in child bedroom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop in bilirubin by 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of optic pathway glioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in cigarettes per day
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence and severity of OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year PSA Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: The occurrence of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: The occurrence of changes in absolute neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The occurrence of changes in alanine transaminase (ALT) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: The occurrence of changes in aldolase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The occurrence of changes in alkaline phosphatase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Decision-making capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ischemia-reperfusion injury tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total abdominal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sonographic cardiac pathologic finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure metric improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System and procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Patient Complications Following Tumor Resection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving a sPGA Score of Clear (0) or Almost Clear (1) for the Facial Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving a sPGA Score of Clear (0) or Almost Clear (1) for the Genital Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Health risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Shift >=3 Changed From Baseline in Eastern Cooperative Oncology Group Performance (ECOG) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OZ439 AUC0-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death from any cardiovascular cause
Endpoint domain: Mortality/survival
Primary endpoint: cerebrovascular infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Estrogen metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progesterone metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hCG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative number of patients withdrawn from up-titration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intraoperative Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Near point of convergence measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Quantitative Hepatitis B Surface Antigen (qHBsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting That They Would Be Likely to See a Healthcare Provider Using Videochat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Scheduled Intervention Phone or Video Calls Completed by Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Usability of Video-Enhanced Care Management for Medically Complex Veterans With CI
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of patients who achieve clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immobile Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Global Neurocognitive Performance z Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: General symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum chloride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Reported Ease of Removal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hand Grip Strength Dynamometer Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Impact Scale (hand domain)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MAdCAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to multiple myeloma
Endpoint domain: Mortality/survival
Primary endpoint: Change in External Knee Moment Abduction (EKAM) during gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trigger finger classification grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline self-reported distress related to somatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Wheelchair Skills Test (WST) 4.1 Capacity Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline plasma metal ion concentrations (Co, Cr, Ni)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apnea-Hypopnea-Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Baseline Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with maintained MMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis of Traumatic Thoracic Aortic Injuries
Endpoint domain: Mortality/survival
Primary endpoint: Tumour response according to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Children's Assessment of Participation and Employment (CAPE)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Self-Efficacy Questionnaire for Children (SEQ-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: level of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete Metabolic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-Hypopnea Index (AHI) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically Meaningful Improvement in Quality-of-Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinically Meaningful Improvement in Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety as measured by clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as measured by vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as measured by ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Stroke Impact Scale (SIS) 3.0 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-Intervention Adverse Events or SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with diurnal IOP ≤ 21 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Flap advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of transfused blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Days Free of Delirium and Coma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Wheelchair Maintenance Training Questionnaire (WMT-Q)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Time Within Glycaemic Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment-emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of nutritional risk factors involved in cognitive decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of Treatment Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Survival at 30 days post-transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy and precision of SVV adjustments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Pathologic Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Perfusion index as an indicator of block success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of the influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tibial union status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Therapeutic efficacy of CHAd63-KH in PKDL lesion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time with BIS in the desired range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of zinc from standard dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogenous fecal zinc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin A absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in accuracy of pCLE images interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue rating scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Progression-free Survival (PFS) at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Sputum Eosinophils (EOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Subjects With ECM Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Major Pocket Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Time Required to Achieve Target Hemoglobin Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieved Target Range of Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 100 Day Transplant-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Neuron-Specific Enolase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Door to Puncture time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days lost to headache disability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: headache pain on a 10-point scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of overall cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with operation complication
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of successful intra-articular deposits of radiocontrast dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: BCI control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Artemether Cmax After First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occult Pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients achieving sUA <6.0 mg/dL, <5.0 mg/dL, <4.0 mg/dL and <3.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fluid volume of Malignant Pleural Effusion and/or Malignant Ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise adherence rating scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of deviation from the guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Pain on Tmj
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best overall response rate in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Fall Risk Factor Management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACU Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Heart Rate Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Appraisal
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Mean Sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Total Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of children with excellent HIV control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSPO Binding Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in Intracellular Emtricitabine Triphosphate (FTC-TP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Intracellular Tenofovir Diphosphate (TFV-DP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meibomian Gland Appearance - Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meibomian Gland Appearance - Mean Reflectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reflex latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to 6 month remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in perianal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of acute surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mammographic breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cushing's Syndrome participant data collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in geometric mean titers ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Maximum Expiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes